T. Rowe Price Associates
CELU icon

T. Rowe Price Associates’s Celularity CELU Stock Holding History

T. Rowe Price Associates’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,120
Closed -$7K – 2899
2023
Q1 		$7K Hold
1,120
– – ﹤0.01% 2893
2022
Q4 		$14K Buy
1,120
+96
+9% +$1.77K ﹤0.01% 2886
2022
Q3 		$24K Buy
+1,024
New +$31.1K ﹤0.01% 2906

Other funds holding CELU

SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
CVSC
C.V. Starr & Co New York $192M AUM 35.69% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $716M AUM 21.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates's CELU Position: Q2 2023 in Review

T. Rowe Price Associates sold out of Celularity (CELU) in Q2 2023, closing a stake of 1,120 shares — an estimated $7K sold.

T. Rowe Price Associates first reported a position in CELU in Q3 2022 and held it in 3 quarters. The position peaked at $24K in Q3 2022. 56 funds tracked by Wall St. Rank hold CELU as of Q2 2023.

  • T. Rowe Price Associates reported no remaining Celularity position as of Q2 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,120 Celularity shares in Q2 2023, an estimated $7K.
  • T. Rowe Price Associates first reported a position in Celularity in Q3 2022 and held it in 3 quarters.
  • T. Rowe Price Associates's Celularity position peaked at $24K in Q3 2022.
  • 56 funds tracked by Wall St. Rank held Celularity as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.